

Veracyte, Inc. Investor Relations Department 6000 Shoreline Court Suite 300 South San Francisco, CA 94080 United States

Visit IR website ☐ Sign-up for Email alerts ☐

7.76
4:00 PM ET Jun 23, 2017
-0.12 🖶 (-1.523%)
7.73 - 8.18
4.83 - 9.71
771,343

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. (more)

## **Stock Performance**



## Press Releases [View all]

Jun 1, 2017

<u>Veracyte to Present at William Blair 2017</u> <u>Growth Stock Conference</u>

May 23, 2017

Veracyte Announces Clinical Validation Data

Demonstrating Envisia™ Genomic

Classifier's Performance in Improving
Idiopathic Pulmonary Fibrosis Diagnosis

Presented at ATS 2017

May 18, 2017

<u>Veracyte Announces Anthem Coverage for</u> <u>the Afirma® Gene Expression Classifier for</u> Use in Thyroid Cancer Diagnosis

May 11, 2017

Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"

May 10, 2017

Veracyte Announces Six Studies Highlighting
Value of Company's Genomic Classifiers in
Lung Cancer and Idiopathic Pulmonary
Fibrosis To Be Presented at ATS 2017

## Financials [View all]

First Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

Apr 21, 2017

Proxy Statement (DEF 14A)

May 3, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)

Aug 3, 2016

Quarterly Report (10-Q)